atezolizumab,cabozantinib
roche
['rcc,(-irccs),(-srcc),(-urcc)', 'contact-3']
the #oncoalerttoptweet day 4 of #asco23 tweet by our faculty present the data on contact-3 trial which addresses a major question in the #mrcc #kidneycancer field is there a role of ici re-challenge? answer is no . this study does 
🌐 Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees 🌎 We are #OncoAlert 🚨